The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended five new medicines this week, including conditional approval of Madrigal Pharmaceuticals’ Rezdiffra for metabolic dysfunction-associated steatohepatitis and Ogsiveo for desmoid tumors. Concurrently, CHMP is re-examining Eli Lilly's Alzheimer's drug Kisunla, amidst ongoing regulatory scrutiny and treatment appraisal in Europe.